Table of Contents
Stock Report
Do not mistake temptation for opportunity.
Generated Tue Apr 17 09:19:04 EDT 2018.
Ratings are relative rankings calculated by finding the lower bound of Wilson score confidence interval. A rating value close to 1 means a higher probablity of a stock's price high vs price open hitting or exceeding Calculated Target.
Mood
Today's mood: 0.4786859297829245
Watched Stocks
Symbol | Rating | Buy | Sell |
---|
Leads
These 16 stocks represent the top 2% of all considered stocks. 2% = 13
Symbol | Rating | Buy | Sell | Mass | Min | Max | Mean | Median | Stdev | Open Vs High |
---|---|---|---|---|---|---|---|---|---|---|
⬇$XRAY1) | 0.871 | 26 | 0 | 15 | 0.046% | 4.072% | 1.233% | 0.851% | 1.202 | |
⬇$SLB2) | 0.799 | 30 | 2 | 44 | 0.286% | 1.792% | 0.835% | 0.583% | 0.473 | |
⬇$EBAY3) | 0.785 | 14 | 0 | 21 | 0.505% | 2.769% | 1.264% | 1.377% | 0.651 | |
⬇$NTAP4) | 0.785 | 14 | 0 | 20 | 0.000% | 2.179% | 0.920% | 0.708% | 0.695 | |
⬇$PEG5) | 0.757 | 12 | 0 | 2 | 0.169% | 1.364% | 0.702% | 0.665% | 0.424 | |
⬇$NUE6) | 0.722 | 10 | 0 | 25 | 0.220% | 3.418% | 1.376% | 0.845% | 1.127 | |
⬇$MRK7) | 0.706 | 78 | 20 | 271 | 0.000% | 1.124% | 0.396% | 0.379% | 0.395 | |
⬇$PPL8) | 0.702 | 14 | 1 | 6 | 0.000% | 0.936% | 0.423% | 0.328% | 0.339 | |
⬇$DISCA9) | 0.676 | 8 | 0 | 3 | 0.113% | 3.707% | 1.180% | 0.518% | 1.306 | |
⬇$DWDP10) | 0.676 | 8 | 0 | 9 | 0.000% | 1.540% | 0.713% | 0.750% | 0.561 | |
⬇$HAL11) | 0.676 | 8 | 0 | 14 | 0.321% | 3.752% | 1.202% | 0.770% | 1.113 | |
⬇$WING12) | 0.676 | 8 | 0 | 6 | 0.000% | 3.251% | 1.449% | 0.893% | 1.291 | |
⬇$MAC13) | 0.610 | 6 | 0 | 11 | 0.227% | 2.378% | 0.920% | 0.896% | 0.603 | |
⬇$NAV14) | 0.610 | 6 | 0 | 25 | 0.024% | 6.706% | 1.392% | 0.769% | 1.941 | |
⬇$DVA15) | 0.566 | 5 | 0 | 10 | 0.104% | 3.780% | 1.238% | 0.980% | 1.180 | |
⬇$MRTN16) | 0.566 | 5 | 0 | 3 | n/a | n/a | n/a | n/a | n/a |
$XRAY
- Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA Inc (NASDAQ: XRAY) and Dynavax (NASDAQ: DVAX) $XRAY https://t.co/cQ40sIbiSG
- 5-star analyst Brandon Couillard from Jefferies reiterated a Buy on $XRAY. https://t.co/K30lVTtZxs
- Dentsply Sirona $XRAY Earns Buy Rating from Jefferies Group https://t.co/1kPZVzBaD1
- Dentsply Sirona $XRAY Earns Buy Rating from Jefferies Group https://t.co/DCuiXLAxxo
- Dentsply Sirona $XRAY Earns “Buy” Rating from Jefferies Group https://t.co/b7QID4cP8b #stocks
- $0.43 Earnings Per Share Expected for Dentsply Sirona $XRAY This Quarter https://t.co/orHezfJZ8U
- Dentsply Sirona $XRAY Expected to Announce Earnings of $0.43 Per Share https://t.co/82Ph8BysWW
- $947.20 Million in Sales Expected for Dentsply Sirona $XRAY This Quarter https://t.co/gV4RKEeXqo
- $947.20 Million in Sales Expected for Dentsply Sirona $XRAY This Quarter https://t.co/1CMmibIpIR
- Dentsply Sirona $XRAY Given “Buy” Rating at Jefferies Group https://t.co/yT96ZB4RnL
- Dentsply Sirona $XRAY Rating Reiterated by Jefferies Group https://t.co/pZgbgVtj74
- Jefferies Group Lowers Dentsply Sirona Q1 2018 Earnings Estimates to $0.43 EPS (Previously $0.47). https://t.co/fAt3nB2RvZ $XRAY #XRAY
- Jefferies Group Analysts Reduce Earnings Estimates for Dentsply Sirona $XRAY https://t.co/GbNCnov6Tm
- Jefferies Group Analysts Reduce Earnings Estimates for Dentsply Sirona $XRAY https://t.co/FFvqDjkZvx #stocks
- $NVCN Press Release from Feb 2018, March regained compliance with TSX, April Boston SCIENTIFIC, Warrants, May Earni… https://t.co/cDJ3uawHcd
$SLB
- RT @ZacksResearch: David Bartosiak gives us the 5 best stocks to trade during the first week of earnings season. $NFLX $SLB $SKX $NUE $LRCX…
- David Bartosiak gives us the 5 best stocks to trade during the first week of earnings season. $NFLX $SLB $SKX $NUE… https://t.co/5omb3YXeKk
- #earnings scheduled for this week $NFLX $BAC $GE $LRCX $GS $UNH $IBM $JNJ $CLF $MTB $ABT $MS $ISRG $PGR $CMA $PG… https://t.co/LkN1AkojVv
- RT @ZacksResearch: David Bartosiak gives us the 5 best stocks to trade during the first week of earnings season. $NFLX $SLB $SKX $NUE $LRCX…
- $SLB Option Order Flow Sentiment is 58.5% Bullish. https://t.co/NF9fBZrueI
- Schlumberger $SLB Receives Average Rating of “Buy” from Brokerages https://t.co/vYM9bao4x9
- Schlumberger $SLB Receives Average Rating of “Buy” from Brokerages https://t.co/v2ezzb6Gpc
- Schlumberger $SLB Receives Average Rating of “Buy” from Brokerages https://t.co/oBJQW3Bvfc
- Big Call Activity https://t.co/B6IlNKq3kX $BHGE $WING $JD $SLB $WDC $TPX $IMAX $AMD $MDXG $GM $ALRM $LVS $IPG $AKRX $AMWD $OLED $TWTR $AAPL
- RT @permabear_uk: Schlumberger $SLB will be the first of the big energy stocks to report this Friday morning. I see a very positive uptick…
- RT @seeitmarket: NEW Article: "National Oilwell Varco (NOV) Cycle Outlook: Stock Topping?" - https://t.co/bxXkHkGBQe by @askSlim $NOV $S…
- Schlumberger seeks to hike patent damages in case before Supreme Court https://t.co/yMd5C3gPWi $IO $SLB $OIH $XES
- RT @AscensionLP: There is a full slate of companies announcing earnings this week, as the banks continue with $BAC on Mon, $GS on Tues, and…
- Chop fest today. Should have traded less but oh well. Still like my $Slb calls going into earnings. With a close ab… https://t.co/djJq1RhjwQ
- RT @seeitmarket: NEW Article: "National Oilwell Varco (NOV) Cycle Outlook: Stock Topping?" - https://t.co/bxXkHkGBQe by @askSlim $NOV $S…
- #Rally $GOOGL $FB $JPM $C $BAC $WFC $AAPL $PM $PG $GE $HON $JNJ $CSCO $MSFT $INTC $TWTR $TSLA $V $DIS $UNH $VZ $KHC… https://t.co/PB4tVzneis
- RT @seeitmarket: NEW Article: "National Oilwell Varco (NOV) Cycle Outlook: Stock Topping?" - https://t.co/bxXkHkGBQe by @askSlim $NOV $S…
- Schlumberger $SLB Given Buy Rating at Instinet https://t.co/6vkCIyNR2k #stocks
- RT @BrandonVanZee: Prep your trading week with this excellent earnings graphic from @eWhispers! $JNJ $PG $NFLX $BAC $GE $LRCX $GS $UNH $I…
- $SLB bought the top here 1/30 I think, jun $75 Calls been averaging down like crazy still negative -55% tho, lets see wha rest of week bring
- RT @ZacksResearch: David Bartosiak gives us the 5 best stocks to trade during the first week of earnings season. $NFLX $SLB $SKX $NUE $LRCX…
- RT @seeitmarket: NEW Article: "National Oilwell Varco (NOV) Cycle Outlook: Stock Topping?" - https://t.co/bxXkHkGBQe by @askSlim $NOV $S…
- RT @eWhispers: #earnings scheduled for the week $NFLX $BAC $GE $LRCX $GS $UNH $IBM $JNJ $CLF $MTB $ABT $MS $ISRG $PGR $CMA $PG $AA $BX $AX…
- RT @eWhispers: #earnings scheduled for the week $NFLX $BAC $GE $LRCX $GS $UNH $IBM $JNJ $CLF $MTB $ABT $MS $ISRG $PGR $CMA $PG $AA $BX $AX…
- RT @Terri1618: $SPY $QQQ $VLO $PSX updates. Slow grind up4 indices reflects indecisive mkt. Don’t force trades w/ sloppy price action. Ener…
- RT @Terri1618: $SPY $QQQ $VLO $PSX updates. Slow grind up4 indices reflects indecisive mkt. Don’t force trades w/ sloppy price action. Ener…
- $SPY $QQQ $VLO $PSX updates. Slow grind up4 indices reflects indecisive mkt. Don’t force trades w/ sloppy price act… https://t.co/RQlQFgB49y
- RT @seeitmarket: NEW Article: "National Oilwell Varco (NOV) Cycle Outlook: Stock Topping?" - https://t.co/bxXkHkGBQe by @askSlim $NOV $S…
- Financial Survey: Schlumberger $SLB versus Basic Energy Services $BAS https://t.co/aeScI0smJm
- RT @Terri1618: $SPY $QQQ $VLO $PSX updates. Slow grind up4 indices reflects indecisive mkt. Don’t force trades w/ sloppy price action. Ener…
- Schlumberger $SLB Receives “Buy” Rating from Cowen https://t.co/VUdLM5mmjq
- RT @eWhispers: #earnings scheduled for the week $NFLX $BAC $GE $LRCX $GS $UNH $IBM $JNJ $CLF $MTB $ABT $MS $ISRG $PGR $CMA $PG $AA $BX $AX…
- RT @Terri1618: $SPY $QQQ $VLO $PSX updates. Slow grind up4 indices reflects indecisive mkt. Don’t force trades w/ sloppy price action. Ener…
- RT @Terri1618: $SPY $QQQ $VLO $PSX updates. Slow grind up4 indices reflects indecisive mkt. Don’t force trades w/ sloppy price action. Ener…
- RT @seeitmarket: NEW Article: "National Oilwell Varco (NOV) Cycle Outlook: Stock Topping?" - https://t.co/bxXkHkGBQe by @askSlim $NOV $S…
- RT @eWhispers: #earnings scheduled for the week $NFLX $BAC $GE $LRCX $GS $UNH $IBM $JNJ $CLF $MTB $ABT $MS $ISRG $PGR $CMA $PG $AA $BX $AX…
- RT @eWhispers: #earnings scheduled for the week $NFLX $BAC $GE $LRCX $GS $UNH $IBM $JNJ $CLF $MTB $ABT $MS $ISRG $PGR $CMA $PG $AA $BX $AX…
- RT @eWhispers: #earnings scheduled for the week $NFLX $BAC $GE $LRCX $GS $UNH $IBM $JNJ $CLF $MTB $ABT $MS $ISRG $PGR $CMA $PG $AA $BX $AX…
- RT @Terri1618: $SPY $QQQ $VLO $PSX updates. Slow grind up4 indices reflects indecisive mkt. Don’t force trades w/ sloppy price action. Ener…
- RT @eWhispers: #earnings scheduled for the week $NFLX $BAC $GE $LRCX $GS $UNH $IBM $JNJ $CLF $MTB $ABT $MS $ISRG $PGR $CMA $PG $AA $BX $AX…
- $SLB Schlumberger Option Order Flow Sentiment is 58.5% Bullish. https://t.co/NF9fBZrueI
- RT @Sarge986: Market Recon: Worried About the Trump Scandal? Buy Planet Fitness $XOM $HAL $SLB $PLNT IBM $CSX $LRCX $UAL https://t.co/b4FR…
- Market Recon: Worried About the Trump Scandal? Buy Planet Fitness $XOM $HAL $SLB $PLNT IBM $CSX $LRCX $UAL https://t.co/b4FREpW5Li
$EBAY
- $EBAY New SEC Document(s) for eBay Inc. From our Stock News Alerts App
- $EBAY eBay Inc. SEC Filing: Form DEFA14A https://t.co/Fx84dGQ0KC
- Evening Most Tweeted Big Caps, check out Gambiste Top 10: $DBX $FAST $CHRW $COST $DISH $AAL $AKAM $EA $BIIB $EBAY https://t.co/lYp5LtitVR
- RT @WarrenBuffetHQ: No matter how fervently one desires to resolve a situation, sometimes it is better to patient and persevere with non-ac…
- RT @Decorporatize: Corps w/#h1b staff are #unAmerican. $INTC $DIS $GOOG $MSFT $IBM $QCOM $NVDA $JPM $AAPL $AMZN $MCD $ORCL $WFC $GS $BAC $H…
- Goldman Sachs looked at 25 tech stocks pulled down by $FB scandal and concludes that there is no connection between… https://t.co/dpMsUfX0Va
- $EBAY: New SEC Filing for EBAY: Form DEFA14A (No. 0001193125-18-118740): https://t.co/keqOv1Mxef
- $GBPUSD $NZDUSD $AUDUSD $EURUSD $SPY $QQQ $JPM $AAPL $AMD $YHOO $USDCAD $TSLA $BAC $ES_F $IBM $CHK $EBAY $WMT $WFC https://t.co/KHvtYikWK5
- Should investors apply to $RKUNY #Rakuten the same multiple they pay for $AMZN Amazon then $RKUNY #Rakuten should b… https://t.co/kf5eECDK5T
- eBay $EBAY Price Target Increased to $34.00 by Analysts at Canaccord Genuity https://t.co/GLVhNdOShT #stocks
- eBay $EBAY Upgraded to “Buy” by Monness Crespi & Hardt https://t.co/FvfqHVSmjt
- eBay $EBAY Upgraded to “Buy” by Monness Crespi & Hardt https://t.co/Z92nUrz0p3
- Online sales tax ---> nexus <--- term of art. Tax accountants/lawyers matter. $AMZN $OSTK $EBAY $W
- John Blackledge previews large-cap Internet earnings $AMZN, $EBAY, $FB, $GOOG, $TWTR
- RT @PlanetZiggurat: https://t.co/VOEUjo0tbD is open $AMZN $EBAY $MELI $ETSY $QVCA $BABA $WMT $COST $TGT $KR $JPM $FB $WFC $GOOG $SNAP $T…
- $WNTR big buyers coming in this month! $GERN $AMZN $NETE $RIOT $TEUM $PTI $COGT $GBLX $RXMD $VEND $GOPH $INTC… https://t.co/5Pfo5dh36a
- Finally starting to trend again $QQQ $SPY $NFLX $AAPL $INTC $EBAY lets go!
$NTAP
- NetApp $NTAP versus Seagate Technology $STX Head to Head Comparison https://t.co/yXjzKcEqr0
- Head to Head Survey: NetApp $NTAP and Seagate Technology $STX https://t.co/BSkhNq4ZvL
- Head to Head Survey: NetApp $NTAP and Seagate Technology $STX https://t.co/o18e6BHT4B #stocks
- Head to Head Survey: NetApp $NTAP and Seagate Technology $STX https://t.co/8WPwmY3TIG
- $MU $WDC $CARB $NTAP $PSTG $STX $SGH https://t.co/IyVLHTggSh
- NetApp $NTAP Coverage Initiated by Analysts at JPMorgan Chase https://t.co/HO6SbRIY3v
- NetApp $NTAP Coverage Initiated by Analysts at JPMorgan Chase https://t.co/htH7NS4x8x
- 5-star analyst Jason Ader from William Blair upgraded rating on $NTAP to Buy. https://t.co/J8xAhn3nxH
- Upgrades $CCE $AXTI $ABB $PHG $TWTR $NTAP $NWL $MRK $DIS $KO $TRMB $DG
- RT @ACInvestorBlog: Upgrades $CCE $AXTI $ABB $PHG $TWTR $NTAP $NWL $MRK $DIS $KO $TRMB $DG
- RT @ACInvestorBlog: Upgrades $CCE $AXTI $ABB $PHG $TWTR $NTAP $NWL $MRK $DIS $KO $TRMB $DG
- Upgrades $CCE $AXTI $ABB $PHG $TWTR $NTAP $NWL $MRK $DIS $KO $TRMB $DG
- William Blair Upgrades NetApp to Outperform Rating $NTAP
- NetApp $NTAP Upgraded to Outperform by William Blair https://t.co/SGElzLqiAd #stocks
- Analyst upgrades NetApp; shares trading at 52-week high https://t.co/4fRpkkBvxu #premarket $NTAP
- Analyst upgrades NetApp; shares trading at 52-week high https://t.co/R7PIgqk5lc #premarket $NTAP
- Analyst upgrades NetApp; shares trading at 52-week high https://t.co/jN3bHmNmH7 #premarket $NTAP
- NetApp $NTAP Raised to Outperform at William Blair https://t.co/LP0EDmgIDa
- NetApp $NTAP Raised to Outperform at William Blair https://t.co/MwbdxIhg9I
- 4/17 52-Week Hi Watch List: $LULU $STX $PXD $URBN $COP $APC $RTN $MLCO $PSX $MPC $NTAP $ADM $VLO $HES $MON $WLL… https://t.co/4Nf7QCFYYD
$PEG
- Public Service Enterprise Group $PEG Upgraded by Bank of America to Buy https://t.co/9vuCyves4Y
- Public Service Enterprise Group $PEG Raised to Buy at Bank of America https://t.co/SQQEg8mWyP
$NUE
- RT @ZacksResearch: David Bartosiak gives us the 5 best stocks to trade during the first week of earnings season. $NFLX $SLB $SKX $NUE $LRCX…
- David Bartosiak gives us the 5 best stocks to trade during the first week of earnings season. $NFLX $SLB $SKX $NUE… https://t.co/5omb3YXeKk
- RT @ZacksResearch: David Bartosiak gives us the 5 best stocks to trade during the first week of earnings season. $NFLX $SLB $SKX $NUE $LRCX…
- #earnings scheduled for this week $NFLX $BAC $GE $LRCX $GS $UNH $IBM $JNJ $CLF $MTB $ABT $MS $ISRG $PGR $CMA $PG… https://t.co/LkN1AkojVv
- RT @BrandonVanZee: Prep your trading week with this excellent earnings graphic from @eWhispers! $JNJ $PG $NFLX $BAC $GE $LRCX $GS $UNH $I…
- $NUE the bull pattern is confirmed & a BUY signal is issued @ https://t.co/SSEzILYJCa. Buy Level: 62.2200 Target: 69.6864
- RT @ZacksResearch: David Bartosiak gives us the 5 best stocks to trade during the first week of earnings season. $NFLX $SLB $SKX $NUE $LRCX…
- Nucor $NUE Earns Buy Rating from Jefferies Group https://t.co/a7AJrdzsTz #stocks
- RT @eWhispers: #earnings scheduled for the week $NFLX $BAC $GE $LRCX $GS $UNH $IBM $JNJ $CLF $MTB $ABT $MS $ISRG $PGR $CMA $PG $AA $BX $AX…
- Nucor $NUE to Release Quarterly Earnings on Thursday https://t.co/9dNqPTf7SE
- Nucor $NUE to Release Quarterly Earnings on Thursday https://t.co/vJ7Wvaketl
- RT @eWhispers: #earnings scheduled for the week $NFLX $BAC $GE $LRCX $GS $UNH $IBM $JNJ $CLF $MTB $ABT $MS $ISRG $PGR $CMA $PG $AA $BX $AX…
- RT @eWhispers: #earnings scheduled for the week $NFLX $BAC $GE $LRCX $GS $UNH $IBM $JNJ $CLF $MTB $ABT $MS $ISRG $PGR $CMA $PG $AA $BX $AX…
- Nucor Co. $NUE Expected to Post Earnings of $1.10 Per Share https://t.co/k38NFon7lL
- Zacks: Analysts Anticipate Nucor Co. $NUE to Announce $1.10 Earnings Per Share https://t.co/0Uab8h10kp
- Zacks: Analysts Anticipate Nucor Co. $NUE to Announce $1.10 Earnings Per Share https://t.co/JY5Yp3sTCU #stocks
- Zacks: Analysts Anticipate Nucor Co. $NUE to Announce $1.10 Earnings Per Share https://t.co/U6c1U9BfXA
- RT @eWhispers: #earnings scheduled for the week $NFLX $BAC $GE $LRCX $GS $UNH $IBM $JNJ $CLF $MTB $ABT $MS $ISRG $PGR $CMA $PG $AA $BX $AX…
- RT @eWhispers: #earnings scheduled for the week $NFLX $BAC $GE $LRCX $GS $UNH $IBM $JNJ $CLF $MTB $ABT $MS $ISRG $PGR $CMA $PG $AA $BX $AX…
- RT @eWhispers: #earnings scheduled for the week $NFLX $BAC $GE $LRCX $GS $UNH $IBM $JNJ $CLF $MTB $ABT $MS $ISRG $PGR $CMA $PG $AA $BX $AX…
- RT @eWhispers: #earnings scheduled for the week $NFLX $BAC $GE $LRCX $GS $UNH $IBM $JNJ $CLF $MTB $ABT $MS $ISRG $PGR $CMA $PG $AA $BX $AX…
- Novid Rassouli previews #steel sector 1Q18 earnings. Focus includes recent pricing trends $X, $MT, $AKS, $STLD, $RS, $NUE, $TMST, $CLF
- $BBT $NUE $BOJA: CBJ Morning Buzz: Could ruling impact SC’s fight with Amazon …: https://t.co/uNSueAWZb5
- $NUE: Is Nucor Shifting Its Growth Approach?: https://t.co/gbZeutPT26
- Target Raised https://t.co/2Wn5XwkMO6 $ICFI $INTC $JBHT $LULU $MA $MB $MNRO $MRK $MTB $NFLX $NUE $RHT $SCHW $STLD $THG $TPR $ULTI $VIAB
$MRK
- RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM $MRK Keynote-189 https://t.co/rkqySZYSLo $BMY Checkmate-227 TMB https://t…
- $MRK $BMY: What Happened in the Stock Market Today: https://t.co/G0RaqxLyCz
- Everything lung cancer! $MRK $BMY #AACR18 https://t.co/evJoPR7Jax
- RT @theflynews: On The Fly: Top stock stories for Monday $AMZN $CVS $WBA $ABC $MCK $CAH $TSLA $NFLX $BAC $WPP $ERI $TPCA $NAV $VLKAY $ACIA…
- Mad Money Lighting Round @jimcramer https://t.co/92gBWvX6Cn $SPOT $ALKS $JNJ $GERN $ILMN $TMO $AKS $SRNE $MITK $NVDA $KKR $FRPT $ABBV $MRK
- RT @JohnCendpts: $BMY not getting much love today -- $MRK in a TKO as analysts score the match. https://t.co/JHlLY14xxm
- RT @JacobPlieth: $MRK crushes $BMY (and perhaps $RHHBY too). My take on today's #AACR18 showdown, via @EPVantage https://t.co/bgoFcCRa1g
- RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM $MRK Keynote-189 https://t.co/rkqySZYSLo $BMY Checkmate-227 TMB https://t…
- #estate assets watch - heaviest volume today: $BAC $GE $BMY $WFC $MU $YNDX $AMD $OCLR $MRK $F $AAPL $RIG $T $CVS… https://t.co/d5eAO7Xvcl
- @bradloncar @sharkbiotech so, per Bristol, $BMY's, $MRK's and like PD1s are not really differentiated in terms of clinical effect?
- RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
- RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM $MRK Keynote-189 https://t.co/rkqySZYSLo $BMY Checkmate-227 TMB https://t…
- RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
- RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
- Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
- RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM $MRK Keynote-189 https://t.co/rkqySZYSLo $BMY Checkmate-227 TMB https://t…
- Bristol-Myers' Opdivo/Yervoy combo beats chemo in first-line lung cancer; shares down 5% on Merck Keytr... https://t.co/Ha37ljKTEs $BMY $MRK
- "There is no question this is a watershed period in the treatment of lung cancer" https://t.co/KQC6A8OUmo $MRK $BMY
- RT @JacobPlieth: $MRK crushes $BMY (and perhaps $RHHBY too). My take on today's #AACR18 showdown, via @EPVantage https://t.co/bgoFcCRa1g
- RT @JacobPlieth: Take that, $BMY. Keytruda's knockout blow in 1st-line NSCLC? $MRK #AACR18 https://t.co/D39w38xTqr
- More Call Activity $FEYE $OSTK $COP $BABA $KHC $OMC $SCHW $NFLX $KNX $EDU $IVC $MRK $ENDP $FCAU $EPD $VLO $PBR $SPHS $NKTR $CTG $BX $WRD
- Big Call Activity https://t.co/B6IlNKq3kX $SCHW $NFLX $KNX $EDU $IVC $MRK $ENDP $FCAU $EPD $VLO $PBR $SPHS $NKTR $CTG $BX $WRD $ICE $JBHT
- RT @tradejas: $MRK Immunotherapy scores big win against lung cancer in study https://t.co/FZaIcaVB2M
- Biotech Updates 04/16: $BMY $MRK lung data $CLDX fail -65% FDA accepts $ALKS NDA $APRI -35% more trials required… https://t.co/tTP5zWxTmz
- RT @bydavidcrow: The story of Bristol vs Merck in one picture $BMY $MRK https://t.co/smszuY6F94
- Part of our strategy includes collaborating with partners to explore new approaches and therapy combinations that c… https://t.co/dnO74dVA7B
- RT @Merck: Looking forward to sharing our latest #cancer research development updates during our #AACR18 investor briefing! $MRK https://t.…
- RT @JohnCendpts: Tim Anderson on $MRK/$BMY brawl: $BMY had some decent numbers for one segment, $MRK did well for all. Bottom line: Keytrud…
- Looking forward to sharing our latest #cancer research development updates during our #AACR18 investor briefing!… https://t.co/YlRaOHgDJf
- RT @AndyBiotech: Novel sexy I/O players now have a mountain to climb vs $MRK chemo combo in lung cancer, plus Alimta going generic by 2022…
- We calculated 63-day Expected Return of $MRK for you: 0.6% https://t.co/y7B8KCv7tv
- $ONCS $MRK Keytruda + Oncosec ep-IL12 in lung cancer would be nice sometime in the future. https://t.co/KrCQti9har
- Today’s $mrk result in NSCLC just affirms to me that it is basically unethical to withhold clinical trial data of a… https://t.co/2UUIKhYKrc
- RT @MaxJacobsEdison: Maybe $MRK should rename their Pembro trials from KEYNOTE to PLENARY.
- RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM $MRK Keynote-189 https://t.co/rkqySZYSLo $BMY Checkmate-227 TMB https://t…
- RT @megtirrell: $MRK data out; Keytruda reduced risk of death in trial by 51% https://t.co/YCSM062iia
- RT @drug_czar: Staggering data from $MRK. OS benefit seen in Intent-to-treat of 0.49 and also all patient subgroups including 0.59 HR in no…
- RT @JohnCendpts: Who won big at #AACR18? Merck surges on Keytruda/chemo combo while Bristol-Myers shares tumble on comparison $MRK +3% $BMY…
- Merck $MRK came out of its corner swinging Sunday morning, taking a few direct jabs at the defending champion in ch… https://t.co/Ku4zE4O9Dg
- $MRK $BMY The Merck vs. Bristol Myers battle isn't over yet, but Merck won today. https://t.co/IHeFBCQ88T
- RT @JohnCendpts: #AACR18 brawl. $MRK data: Keytruda/chemo reduces risk of death by 51% -- in high PD-L1 58%. HR of 0.49. https://t.co/4Kpcx…
- RT @JacobPlieth: Take that, $BMY. Keytruda's knockout blow in 1st-line NSCLC? $MRK #AACR18 https://t.co/D39w38xTqr
- Why Merck Is Betting Big on One Cancer Drug Global sales of more than $3.8 billion for Keytruda in 2017 spur effor… https://t.co/NArrmtoPcv
- RT @megtirrell: $MRK data out; Keytruda reduced risk of death in trial by 51% https://t.co/YCSM062iia
- $MRK Immunotherapy scores big win against lung cancer in study https://t.co/FZaIcaVB2M
- RT @drug_czar: Head still spinning from the IO showdown at #AACR18? To keep track of the data, I have a comparison of the PFS and OS hazard…
- $IMMP $MRK https://t.co/C7KqFIvqUB
- RT @VistaPResearch: Read "Positively Doubting Judgement?” Vista Partners Weekly Market Update 4-14-18 https://t.co/hg3CNxxgeF #investing #…
- $MRK nice options flow..i see 1 put on the whole list https://t.co/b8X2eLt80N
- Shares of Bristol-Myers Squibb fell after its drug was surpassed by Keytruda’s performance.… https://t.co/0lgRNkSl3z
- RT @drug_czar: Head still spinning from the IO showdown at #AACR18? To keep track of the data, I have a comparison of the PFS and OS hazard…
- @drug_czar $MRK has a history of deceptive practices. You can't trust them. Here's one of many examples. https://t.co/4qEQahWIuy
- $MRK regardless if you have a position or not, you have to truly appreciate what they have done with Keytruda. Amazing accomplishment @Merck
- RT @JohnCendpts: #AACR18 brawl. $MRK data: Keytruda/chemo reduces risk of death by 51% -- in high PD-L1 58%. HR of 0.49. https://t.co/4Kpcx…
- RT @theflynews: On The Fly: Top stock stories for Monday $AMZN $CVS $WBA $ABC $MCK $CAH $TSLA $NFLX $BAC $WPP $ERI $TPCA $NAV $VLKAY $ACIA…
- #estate asset watch - price / volume leaders today: $BAC $GE $BMY $WFC $MU $AMD $YNDX $OCLR $MRK $AAPL $F $T $RIG… https://t.co/V6HHzetULl
- Dow Jones Analysis Video - $DJIA $DIA $SDOW $XOM $GE $GS $MRK $PFE $BMY $VZ https://t.co/DKVRp58o9M #stockmarket #stocks #trading #DowJones
- Dow Jones Analysis Video - $DJIA $DIA $SDOW $XOM $GE $GS $MRK $PFE $BMY $VZ https://t.co/tE01Lw1rzM #stockmarket #stocks #trading #DowJones
- RT @JohnCendpts: #2 Who won big at #AACR18? Merck surges on Keytruda/chemo combo while Bristol-Myers shares tumble on comparison $MRK $BMY…
- RT @JohnCendpts: #3 #AACR18 round 1: Merck takes a direct swing at Bristol-Myers with adjuvant melanoma data for Keytruda $MRK $BMY https:/…
- @Sanctuary_Bio The difference is $MRK has good revenue growth and will just grow faster with the 1L chemo+Keytruda… https://t.co/6AOeZv166q
- RT @JohnCendpts: $BMY not getting much love today -- $MRK in a TKO as analysts score the match. https://t.co/JHlLY14xxm
- RT @JacobPlieth: $MRK crushes $BMY (and perhaps $RHHBY too). My take on today's #AACR18 showdown, via @EPVantage https://t.co/bgoFcCRa1g
- RT @matthewherper: My story on the $mrk $bmy data. Short version: $mrk wins again, despite strong $bmy results. https://t.co/0phBvFJd5m
- RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
- RT @JacobPlieth: Probably the most positive slide for $BMY in CM-227, via M Hellmann #AACR18 $MRK $RHHBY https://t.co/jWPi8Qx3ll
- RT @crusadernz: Biotech Updates 04/16: $BMY $MRK lung data $CLDX fail -65% FDA accepts $ALKS NDA $APRI -35% more trials required $CLVS -10…
- RT @JacobPlieth: Justin Gainor (Impower-150 discussant) compares KN-189 vs IMP-150. We LOVE cross-trial comparisons, right? $MRK $RHHBY $BM…
- RT @crusadernz: Biotech Updates 04/16: $BMY $MRK lung data $CLDX fail -65% FDA accepts $ALKS NDA $APRI -35% more trials required $CLVS -10…
- RT @Merck: “This year’s @AACR Annual Meeting represents an important milestone for immuno-oncology research and we’re extremely proud to ha…
- RT @Merck: “This year’s @AACR Annual Meeting represents an important milestone for immuno-oncology research and we’re extremely proud to ha…
- RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
- Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new… https://t.co/MBzG3oWQC5
- RT @Merck: “This year’s @AACR Annual Meeting represents an important milestone for immuno-oncology research and we’re extremely proud to ha…
- RT @Merck: Looking forward to sharing our latest #cancer research development updates during our #AACR18 investor briefing! $MRK https://t.…
- RT @Merck: “This year’s @AACR Annual Meeting represents an important milestone for immuno-oncology research and we’re extremely proud to ha…
- RT @Merck: “This year’s @AACR Annual Meeting represents an important milestone for immuno-oncology research and we’re extremely proud to ha…
- RT @Merck: Don't miss important new data from our #LungCancer study being presented today at #AACR18. Learn more here: https://t.co/DRFdeti…
- “This year’s @AACR Annual Meeting represents an important milestone for immuno-oncology research and we’re extremel… https://t.co/F59gQJw4oO
- RT @Merck: Looking forward to sharing our latest #cancer research development updates during our #AACR18 investor briefing! $MRK https://t.…
- In KEYNOTE-054, adjuvant treatment with $MRK's Keytruda of Stage 3 melanoma reduced the risk of disease recurrence… https://t.co/vLRcder2Od
- This is a stunning…Keytruda and Optiva are game-changers for lung (and probably other) cancer, and home-runs for… https://t.co/bMPJ6sosUk
- Slides from $MRK AACR investor webcast: https://t.co/FuG1GWrg5c
- $LPTX Reveals findings from study testing DKN-01 + $MRK 's KEYTRUDA in patients with advanced esophagogastric cancer https://t.co/k3lwjC7qkG
- $LPTX Reveals findings from study testing DKN-01 + $MRK 's KEYTRUDA in patients with advanced esophagogastric cance… https://t.co/4vbceutrCV
- RT @Merck: Don't miss important new data from our #LungCancer study being presented today at #AACR18. Learn more here: https://t.co/DRFdeti…
- One has to wonder how Nivo/Chemo compares with Pembro/Chemo. I suspect in CM-227 Part 1b, Nivo/chemo was no better… https://t.co/miAz9fXKE3
- Nothing was said about Part 1b, which compares nivo/ipi, Nivo/Chemo, and Chemo alone in PDL-1 - patients. This part… https://t.co/3sgN4jrMc5
- @megtirell Impressive results for $MRK & $BMY in the battle against lung cancer. https://t.co/cEaDKvvZij
- RT @IBD_AGatlin: Can this smaller biotech actually rival Merck, Bristol in cancer drugs? $TSRO $MRK $BMY https://t.co/4XMvQlXf5t
- RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
- RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
- RT @crusadernz: Biotech Updates 04/16: $BMY $MRK lung data $CLDX fail -65% FDA accepts $ALKS NDA $APRI -35% more trials required $CLVS -10…
- RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
- RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
- RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
- @gcbioinv @Kevvy_Kaye Hi, buddies. With today's $MRK and $BMY lung cancer data, I have a feeling that majority of o… https://t.co/D6YpmWReeN
- RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM $MRK Keynote-189 https://t.co/rkqySZYSLo $BMY Checkmate-227 TMB https://t…
- RT @jonathanrockoff: $MRK up >2.5%, while $BMY down >8%, on lung-cancer immunotherapy news: https://t.co/PfjUipfQEr. Bernstein's Anderson s…
- RT @JacobPlieth: Justin Gainor (Impower-150 discussant) compares KN-189 vs IMP-150. We LOVE cross-trial comparisons, right? $MRK $RHHBY $BM…
- RT @JohnCendpts: #2 Who won big at #AACR18? Merck surges on Keytruda/chemo combo while Bristol-Myers shares tumble on comparison $MRK $BMY…
- RT @JacobPlieth: $MRK crushes $BMY (and perhaps $RHHBY too). My take on today's #AACR18 showdown, via @EPVantage https://t.co/bgoFcCRa1g
- Okay. So $BMY = bad company & great stock and, $MRK = Great company and bad stock. I will never understand how '… https://t.co/RqDzvSlQ68
- RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
- RT @Ogut_Ozgur: Today’s $mrk result in NSCLC just affirms to me that it is basically unethical to withhold clinical trial data of approved…
- RT @JacobPlieth: Take that, $BMY. Keytruda's knockout blow in 1st-line NSCLC? $MRK #AACR18 https://t.co/D39w38xTqr
- RT @bydavidcrow: Here are my back of envelope comparisons on Merck and Bristol trials (I know, no cross trial comps yadayada, but everyone…
- RT @DewDiligence: Slides from $MRK AACR investor webcast: https://t.co/FuG1GWrg5c
- Recommendation #HOLD for $MRK with UB rating - 2.89 out of 5. https://t.co/QmN7roMsl8
- RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
- RT @BursatilBiotech: Gooooooooooooooooooooooooooood Morning, Deareeeeest Biotwitter! Toooooooooday is D-Day! 1 disease, 3 COs, 3 trials $B…
- @Ogut_Ozgur As BMO put it: "Keytruda + chemo is the new standard of care in all ALK/EGFR negative noon-squamous 1L-… https://t.co/Mc1V0xgUiZ
- RT @AndyBiotech: #Biotech Busy week ahead! $RARE PDUFA $RIGL PDUFA $GWPH AdCom $INCY $LLY AdCom BD Earnings $JNJ $NVS #AACR18 $BMY CM-227…
- RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
- RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
- RT @JacobPlieth: Probably the most positive slide for $BMY in CM-227, via M Hellmann #AACR18 $MRK $RHHBY https://t.co/jWPi8Qx3ll
- RT @JacobPlieth: $MRK crushes $BMY (and perhaps $RHHBY too). My take on today's #AACR18 showdown, via @EPVantage https://t.co/bgoFcCRa1g
- RT @SA_BioTech: $AXON $BIIB $LLY $MRK $VTVT https://t.co/hPZRl4rPeM
- RT @AndyBiotech: #Biotech Busy week ahead! $RARE PDUFA $RIGL PDUFA $GWPH AdCom $INCY $LLY AdCom BD Earnings $JNJ $NVS #AACR18 $BMY CM-227…
- $LPTX $7.83 +0.34 (4.54%) $MRK $59.24 +0.59 (1.01%) - News Out https://t.co/aSsM2rGugR
- Explore #fundamental numbers and pros and cons for $MRK https://t.co/RMKJb2hbiB
- #Merck Cements Lead in #Lungcancer With #BristolMyers Fizzling #Competition between #pharma is good for #patients… https://t.co/Bn0zKdCJSd
- RT @Merck: “This year’s @AACR Annual Meeting represents an important milestone for immuno-oncology research and we’re extremely proud to ha…
- Wondering about risks of $MRK? The 21-day volatility is 7.33% https://t.co/F24Y08wWlG
- RT @Merck: Looking forward to sharing our latest #cancer research development updates during our #AACR18 investor briefing! $MRK https://t.…
- RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
- $MRK high OI range is 55.00 to 57.50 for option expiration 04/20/2018 #maxpain #options https://t.co/biZK1ZVXxB https://t.co/buidhxn7hO
- Wondering about risks of $MRK? The 63-day volatility is 12.7% https://t.co/F24Y08wWlG
- We calculated 63-day Expected Return of $MRK for you: 0.6% https://t.co/eHMiSmPb0G
- I bet the $ONCS partner to b announced soon will be $MRK. Wouldn’t be surprised to ultimately see them combine key… https://t.co/QHVbzOSW1y
- RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
- @JohnTuckerPhD @bradloncar It’s all trial design- $MRK said why beat chemo when you can join it. Blame $BMY for bei… https://t.co/KnLFt1EvFH
- RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
- RT @BioPharmaDive: In KEYNOTE-054, adjuvant treatment with $MRK's Keytruda of Stage 3 melanoma reduced the risk of disease recurrence or de…
- RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
- @JSTBiotech I'm not worried about that. Part of the reason for the weakness is great $MRK data for CP + chemo. Anyo… https://t.co/4TPrzTj43u
- RT @AndyBiotech: #Biotech Busy week ahead! $RARE PDUFA $RIGL PDUFA $GWPH AdCom $INCY $LLY AdCom BD Earnings $JNJ $NVS #AACR18 $BMY CM-227…
- RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
- RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
- RT @Merck: Looking forward to sharing our latest #cancer research development updates during our #AACR18 investor briefing! $MRK https://t.…
- RT @Merck: Part of our strategy includes collaborating with partners to explore new approaches and therapy combinations that could help peo…
- RT @AndyBiotech: #Biotech Busy week ahead! $RARE PDUFA $RIGL PDUFA $GWPH AdCom $INCY $LLY AdCom BD Earnings $JNJ $NVS #AACR18 $BMY CM-227…
- RT @Merck: “This year’s @AACR Annual Meeting represents an important milestone for immuno-oncology research and we’re extremely proud to ha…
- RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
- $MRK on watch
- RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM $MRK Keynote-189 https://t.co/rkqySZYSLo $BMY Checkmate-227 TMB https://t…
- RT @JacobPlieth: $RHHBY Impower-150 PFS results by PD-L1 status, via Mark Socinski (note two different assays...) #AACR18 $MRK $BMY https:/…
- RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
- RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM $MRK Keynote-189 https://t.co/rkqySZYSLo $BMY Checkmate-227 TMB https://t…
- RT @JacobPlieth: That's clear, right? (Matthew Hellmann, Checkmate-227 redesign.) #AACR18 $BMY $MRK $RHHBY https://t.co/agIwItrdCX
- RT @JacobPlieth: Probably the most positive slide for $BMY in CM-227, via M Hellmann #AACR18 $MRK $RHHBY https://t.co/jWPi8Qx3ll
- RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
- RT @Merck: Part of our strategy includes collaborating with partners to explore new approaches and therapy combinations that could help peo…
- RT @JacobPlieth: Take that, $BMY. Keytruda's knockout blow in 1st-line NSCLC? $MRK #AACR18 https://t.co/D39w38xTqr
- Research Analysts Offer Predictions for Merck & Co.’s Q1 2018 Earnings $MRK https://t.co/tn0qmtsdMN
- Research Analysts Offer Predictions for Merck & Co.’s Q1 2018 Earnings $MRK https://t.co/N254C48l3y
- RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM $MRK Keynote-189 https://t.co/rkqySZYSLo $BMY Checkmate-227 TMB https://t…
- RT @bydavidcrow: Here are my back of envelope comparisons on Merck and Bristol trials (I know, no cross trial comps yadayada, but everyone…
- RT @AndyBiotech: #Biotech Busy week ahead! $RARE PDUFA $RIGL PDUFA $GWPH AdCom $INCY $LLY AdCom BD Earnings $JNJ $NVS #AACR18 $BMY CM-227…
- RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM $MRK Keynote-189 https://t.co/rkqySZYSLo $BMY Checkmate-227 TMB https://t…
- $ALKS $BMY $JNJ $MRK https://t.co/8u9uVNGt0n
- RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
- RT @JacobPlieth: Take that, $BMY. Keytruda's knockout blow in 1st-line NSCLC? $MRK #AACR18 https://t.co/D39w38xTqr
- RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM $MRK Keynote-189 https://t.co/rkqySZYSLo $BMY Checkmate-227 TMB https://t…
- RT @endpts: Who won big at #AACR18? Merck surges on Keytruda/chemo combo while Bristol-Myers shares tumble on comparison https://t.co/zhvTj…
- RT @kjilly: #IO combos inch forward in #pharma's #lungcancer quest #biotech #biopharma #biotechnology #NSCLC #AACR18 #immunooncology #Opdiv…
- Who won big at #AACR18? Merck surges on Keytruda/chemo combo while Bristol-Myers shares tumble on comparison… https://t.co/wlpUREtYNC
- Read "Positively Doubting Judgement?” Vista Partners Weekly Market Update https://t.co/hg3CNxxgeF #investing… https://t.co/iAX3jLzftz
- RT @JohnCendpts: #AACR18 brawl. $MRK data: Keytruda/chemo reduces risk of death by 51% -- in high PD-L1 58%. HR of 0.49. https://t.co/4Kpcx…
- RT @SeekingAlpha: $ALKS $BMY $JNJ $MRK https://t.co/8u9uVNGt0n
- The past week $BMY had been going DOWN while $MRK had been creeping UP. Something tells me the cancer trial informa… https://t.co/G6rioVSzZW
- RT @JacobPlieth: $MRK crushes $BMY (and perhaps $RHHBY too). My take on today's #AACR18 showdown, via @EPVantage https://t.co/bgoFcCRa1g
- RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
- Jefferies Group Reiterates $56.00 Price Target for Merck & Co. $MRK https://t.co/NU4cNLyYJE
- RT @zbiotech: spectacular NEJM data $MRK 189 OS KM and subgroups https://t.co/8cQz63yFw3
- While everyone's chewing on the data and the Merck vs BMS / pembro vs nivo discussion, let's not forget about the i… https://t.co/wXneEoRnvL
- RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM $MRK Keynote-189 https://t.co/rkqySZYSLo $BMY Checkmate-227 TMB https://t…
- @jq1234t @bradloncar A PD-L1+/- analysis of CM-227 be when $MRK Keytruda+chemo can be used in all-comers, and Keytr… https://t.co/9U1zzd4wea
- A loophole for $bmy in 1st line nsclc might be the relatively high number of patients with symptomatic brainmets. D… https://t.co/cnGoFDhjfJ
- RT @Ogut_Ozgur: Today’s $mrk result in NSCLC just affirms to me that it is basically unethical to withhold clinical trial data of approved…
- RT @drug_czar: Head still spinning from the IO showdown at #AACR18? To keep track of the data, I have a comparison of the PFS and OS hazard…
- RT @Ogut_Ozgur: Today’s $mrk result in NSCLC just affirms to me that it is basically unethical to withhold clinical trial data of approved…
- RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
- RT @DewDiligence: Slides from $MRK AACR investor webcast: https://t.co/FuG1GWrg5c
- Morgan Stanley Upgrades Merck $MRK to Overweight https://t.co/Cihq17yxzY
- RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
- RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM $MRK Keynote-189 https://t.co/rkqySZYSLo $BMY Checkmate-227 TMB https://t…
- @jq1234t @bradloncar A PD-L1+/- analysis of CM-227 when $MRK Keytruda+chemo can be used in all-comers, and Keytruda… https://t.co/X4bqi6c38C
- RT @OpenOutcrier: $MRK (+0.5% pre) Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percen…
- RT @OpenOutcrier: $MRK (+0.5% pre) Why Merck Is Betting Big on One Cancer Drug - WSJ https://t.co/5vMoVT25L7
- Lung Cancer Patients Live Longer With Immune Therapy https://t.co/okEy7qE06W $BMY $MRK
- RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
- RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
- RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM $MRK Keynote-189 https://t.co/rkqySZYSLo $BMY Checkmate-227 TMB https://t…
- RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
- #Premarket Top % Gainers: $ASFI 8%, $ROKU $NFLX $YANG $HMNY $TWTR $TQQQ $ZUO $DGAZ $YNDX $TEO $NOK $PHG $HMY $MRK $IQ $PSEC $SSO $BUD $SHPG
- RT @wboscoho: $BMY $MRK RT Lung Cancer Patients Live Longer With Immune Therapy https://t.co/2KjXaTWSqH
- $MRK upgraded to Overweight at Morgan Stanley. PT $68
- $BMY $MRK RT Lung Cancer Patients Live Longer With Immune Therapy https://t.co/2KjXaTWSqH
- RT @BioStocks: $MRK upgraded to Overweight at Morgan Stanley. PT $68
- RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
- RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
- RT @drug_czar: With a week left to go, here's a preview of the Immunotherapy-combo showdown at #AACR18 where Keytruda, Opdivo, and Tecentri…
- Merck & Co.’s $MRK “Buy” Rating Reaffirmed at BMO Capital Markets https://t.co/q0k1NytbBk
- RT @BioStocks: $MRK upgraded to Overweight at Morgan Stanley. PT $68
- RT @BioStocks: $MRK upgraded to Overweight at Morgan Stanley. PT $68
- $MRK upgraded to Overweight at Morgan Stanley. PT $68
- Baml $MRK emerging as clear IO leader in lung cancer raising Keytruda sales forecasts based on strength of Phase 3… https://t.co/FYpKjLZ3PF
- RT @drug_czar: Head still spinning from the IO showdown at #AACR18? To keep track of the data, I have a comparison of the PFS and OS hazard…
- RT @BobbyLandman121: Keynote189 vs IMpower150 comparison $MRK $AZN #AACR18 https://t.co/1AdTLNHLDj
- ‘Keytruda is King’ in lung cancer, putting BMS and next-gen in the shade https://t.co/OILpNPRbjN #AACR18 $MRK $NKTR $BMS
- RT @wboscoho: $BMY $MRK RT Lung Cancer Patients Live Longer With Immune Therapy https://t.co/2KjXaTWSqH
- RT @Super1NYC: #Premarket Top % Gainers: $ASFI 8%, $ROKU $NFLX $YANG $HMNY $TWTR $TQQQ $ZUO $DGAZ $YNDX $TEO $NOK $PHG $HMY $MRK $IQ $PSEC…
- Upgrades $CCE $AXTI $ABB $PHG $TWTR $NTAP $NWL $MRK $DIS $KO $TRMB $DG
- RT @ACInvestorBlog: Upgrades $CCE $AXTI $ABB $PHG $TWTR $NTAP $NWL $MRK $DIS $KO $TRMB $DG
- RT @ACInvestorBlog: Upgrades $CCE $AXTI $ABB $PHG $TWTR $NTAP $NWL $MRK $DIS $KO $TRMB $DG
- https://t.co/2WASIf0beT $JNJ $PFE $MRK #earnings #pharmastock #Cancer #stocknews #Markets
- RT @bydavidcrow: Here are my back of envelope comparisons on Merck and Bristol trials (I know, no cross trial comps yadayada, but everyone…
- RT @bydavidcrow: Credit Suisse calls it for Merck $MRK $BMY https://t.co/mIhbsL4ePj
- RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
- RT @Super1NYC: #Premarket Top % Gainers: $ASFI 8%, $ROKU $NFLX $YANG $HMNY $TWTR $TQQQ $ZUO $DGAZ $YNDX $TEO $NOK $PHG $HMY $MRK $IQ $PSEC…
- RT @tgtxdough: LADEN $LPTX 2nd note LPTX Stock Drop After DKN-01+Keytruda AACR2018 Data Unwarranted; Reiterate Buy PT 18 $MRK #AACR18 https…
- RT @BioStocks: $MRK upgraded to Overweight at Morgan Stanley. PT $68
- RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
- RT @Super1NYC: #Premarket Top % Gainers: $ASFI 8%, $ROKU $NFLX $YANG $HMNY $TWTR $TQQQ $ZUO $DGAZ $YNDX $TEO $NOK $PHG $HMY $MRK $IQ $PSEC…
- RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
- Steve Scala publishes pharma sector investment takeaways from #AACR18 $MRK $BMY $AZN $RHHBY
- Further $LPTX commentary from Laden - treating physician called one patient's response "a miracle" and Merck $MRK "… https://t.co/yK5AqFdeCp
- RT @Merck: Looking forward to sharing our latest #cancer research development updates during our #AACR18 investor briefing! $MRK https://t.…
- RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
- Merck & Co. $MRK Upgraded to “Buy” by Morgan Stanley https://t.co/RFWxaLR3B6
- RT @tgtxdough: LADEN $LPTX 2nd note LPTX Stock Drop After DKN-01+Keytruda AACR2018 Data Unwarranted; Reiterate Buy PT 18 $MRK #AACR18 https…
- RT @tgtxdough: LADEN $LPTX 2nd note LPTX Stock Drop After DKN-01+Keytruda AACR2018 Data Unwarranted; Reiterate Buy PT 18 $MRK #AACR18 https…
- LADEN $LPTX 2nd note LPTX Stock Drop After DKN-01+Keytruda AACR2018 Data Unwarranted; Reiterate Buy PT 18 $MRK… https://t.co/Boe63UmTcn
- Merck & Co. $MRK Upgraded to “Buy” by Morgan Stanley https://t.co/G9bAXnHVrw
- PM Top % Gainers: $CNET $DPW $ROKU $ARQL $NFLX $AVXL $TQQQ $IQ $DBX $TWTR $UNH $NOK $HMNY $SPXL $MRK $RAD $HMY $BUD $AMD
- Gainers Premarket $ROKU $NFLX $TQQQ $TWTR $DGAX $UPRO $QLD $SPXL $NOK $UNH $MRK $TNA $AMD $BUD $SHPG $SSO https://t.co/jpobP3U3HN
- #TRADING US PM Gapers $NFLX $UNH $ROKU $SHPG $BUD $MRK $WPP $TWTR $RDS.A $PHG $YNDX $BAC $HMNY $AMD $NOK $HMY $BABA… https://t.co/dp6OhUSF3P
- RT @Super1NYC: #Premarket Top % Gainers: $CNET 30%, $DPW 15%, $ROKU $ARQL $NFLX $AVXL $TQQQ $IQ $DBX $TWTR $UNH $NOK $HMNY $SPXL $MRK $RAD…
- Upgrades $CCE $AXTI $ABB $PHG $TWTR $NTAP $NWL $MRK $DIS $KO $TRMB $DG
- $KTOV Highlights of TyrNovo's NT-219 recent promising results from Kitov last presentation #AACR18 $MRK $LLY https://t.co/9Yi3pa6CnV
- JPM currently assumes 45% mkt share for $MRK which could proove conservative, each additional 10% share bumps peak… https://t.co/qYCk3PTo4X
- GS - $BMY data was solid but significantly overshadowed by $MRK
- $NKTR Wainwright attributes selloff to belief that $MRK has first mover advantage in non-squamous NSCLC. Believes… https://t.co/IcqXdSpzDN
- $MRK Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine https://t.co/XUj8XMe0Kt
- $MRK: Merck Announces First Phase Three Studies for PCV-15 (V114) Its …: https://t.co/cPkzYUs8hm
- $MRK Pretty sure Merck was buying back their own shares last quarter. Merck going to $70 this year for sure. https://t.co/REtHfcs3yY
- $MRK Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine https://t.co/QJxt6U62z3
- RT @Super1NYC: #Premarket Top % Gainers: $CNET 30%, $DPW 15%, $ROKU $ARQL $NFLX $AVXL $TQQQ $IQ $DBX $TWTR $UNH $NOK $HMNY $SPXL $MRK $RAD…
- RT @Super1NYC: #Premarket Top % Gainers: $ASFI 8%, $ROKU $NFLX $YANG $HMNY $TWTR $TQQQ $ZUO $DGAZ $YNDX $TEO $NOK $PHG $HMY $MRK $IQ $PSEC…
- Given the examples in the article, $MRK $RHHBY $PFE $GILD $KITE $SNY $CELG and DOZEN more from $XBI $IBB should be… https://t.co/cB5l1rNwld
- $MRK: GapUP 1.25[+2.1%,fill:27%], PrvCl:58.65, PrvHi:59.25, 1NewHi, PDayGp+, 47:6Accel+, allTFs+, bigFlt:2.7B, 1MoHi+, p$vol:3.85M
- RT @JSTBiotech: Further $LPTX commentary from Laden - treating physician called one patient's response "a miracle" and Merck $MRK "encourag…
- $NVCN Press Release from Feb 2018, March regained compliance with TSX, April Boston SCIENTIFIC, Warrants, May Earni… https://t.co/1Zrt1sMbAP
- $MRK Well done. Crossing SMA200.
- Merck & Co. $MRK Raised to “Buy” at Morgan Stanley https://t.co/OfgzOYMsAV #stocks
- RT @tgtxdough: $MRK #KEYTRUDA Currently have 759 trials listed on https://t.co/0g3i1CrgVf o Studying >400 combos o 12 breakthrough therapie…
- MS $MRK upgrading MRK from EW to OW raising PT from $63 to $68. Keytruda showed better-than-expected KN-189 lung re… https://t.co/35t7vYVxVv
- GS - $MRK emerged the clear winner post AACR investor presentation, incremental 10% gain in mkt share (at minimum)… https://t.co/6EeetYjODR
- RT @tgtxdough: $MRK #KEYTRUDA Currently have 759 trials listed on https://t.co/0g3i1CrgVf o Studying >400 combos o 12 breakthrough therapie…
- $MRK #KEYTRUDA Currently have 759 trials listed on https://t.co/0g3i1CrgVf o Studying >400 combos o 12 breakthrough… https://t.co/NGpGOuTWCi
- #Premarket Top % Gainers: $CNET 30%, $DPW 15%, $ROKU $ARQL $NFLX $AVXL $TQQQ $IQ $DBX $TWTR $UNH $NOK $HMNY $SPXL… https://t.co/9Hmd2x5bmc
- Merck & Co.’s $MRK “Buy” Rating Reaffirmed at BMO Capital Markets https://t.co/ow2AF2hnaE
- RT @BioStocks: $MRK upgraded to Overweight at Morgan Stanley. PT $68
- Intensity is the price of excellence $MYMX The Best Stock Investment For 2018 HIV Vaccine 100% Effective Now At… https://t.co/XRwNiO3ou2
- RT @dixielee1969: PM Top % Gainers: $CNET $DPW $ROKU $ARQL $NFLX $AVXL $TQQQ $IQ $DBX $TWTR $UNH $NOK $HMNY $SPXL $MRK $RAD $HMY $BUD $AMD
- Target Raised https://t.co/2Wn5XwkMO6 $ICFI $INTC $JBHT $LULU $MA $MB $MNRO $MRK $MTB $NFLX $NUE $RHT $SCHW $STLD $THG $TPR $ULTI $VIAB
$PPL
- $PPL Stock Quote Alert for PPL Corporation (NYSE:PPL) From our Stock News Alerts App
- Short volume percent for $XEL on 2018-04-13 is 54%. https://t.co/uLgZeax2Ne $PPL 67% $CMS 45% $AVA 37% $IDA 36%
- Scan results - Crossed Above 50 DMA today: $CMMC $ENGH $ITX $U $QBR.B $LXG $SVI $PPL ... https://t.co/g75Ixenriv
- $PPL - PPL #PPL Upgraded by Jefferies Group to "Buy" https://t.co/MGLLU3kPqp
- PPL $PPL Upgraded by Jefferies Group to “Buy” https://t.co/ZjKiWq5kFT #stocks
- $PPL technical alerts: Crossed Above 50 DMA, Stochastic Reached Overbought, and New Uptrend https://t.co/cKRApFfjhS
$DISCA
- $DISCA open interest for maturity 04/20/2018. High put=22.50 High call=25.00 #maxpain #options… https://t.co/onPbIQjlS6
- Barrington Keeps Their Buy Rating on Discovery Comms $DISCA https://t.co/p4ZBGGrEFE
- Discovery $DISCA Given “Buy” Rating at Barrington Research https://t.co/m62DKHu90m #stocks
$DWDP
- Dow Chemical $DWDP Getting Somewhat Favorable Press Coverage, Accern Reports https://t.co/0LAGCdF0zp
- Dow Chemical $DWDP Getting Somewhat Favorable Press Coverage, Accern Reports https://t.co/2OL8v85WuU
- SunTrust Banks Weighs in on Dow Chemical’s Q1 2018 Earnings $DWDP https://t.co/8gWSJHYo1Y
- SunTrust Banks Weighs in on Dow Chemical’s Q1 2018 Earnings $DWDP https://t.co/mTUR0zTlyl
- DowDuPont Inc Gets a Buy Rating from RBC Capital $DWDP https://t.co/EPoC5jOTj6
- Dow Chemical's buy rating reiterated at Royal Bank of Canada. $85.00 PT. https://t.co/193zAqppE0 $DWDP #DWDP
- Dow Chemical’s $DWDP “Buy” Rating Reiterated at Royal Bank of Canada https://t.co/Tkz7JREze9
- Royal Bank of Canada Reaffirms “Buy” Rating for Dow Chemical $DWDP https://t.co/TA0FoYLljz #stocks
- Look for investments that are easy to understand $MYMX The Best Stock Investment For 2018 HIV Vaccine 100% Effect… https://t.co/BKMnJMfJDd
$HAL
- RT @seeitmarket: NEW Article: "National Oilwell Varco (NOV) Cycle Outlook: Stock Topping?" - https://t.co/bxXkHkGBQe by @askSlim $NOV $S…
- Victory Formation Long/Short Portfolio Update - Buy Gold, Oil, And Disney https://t.co/oPD8MfdU1d $DIS, $ADM, $BHP,… https://t.co/ZHYqMBeFtp
- Investors Buy Halliburton $HAL on Weakness https://t.co/iAvwsIRRQy
- Traders Buy Shares of Halliburton $HAL on Weakness https://t.co/WOHxx4dYIV
- RT @seeitmarket: NEW Article: "National Oilwell Varco (NOV) Cycle Outlook: Stock Topping?" - https://t.co/bxXkHkGBQe by @askSlim $NOV $S…
- RT @seeitmarket: NEW Article: "National Oilwell Varco (NOV) Cycle Outlook: Stock Topping?" - https://t.co/bxXkHkGBQe by @askSlim $NOV $S…
- Money Flows--Buying on Weakness: Among stocks that were ⬇️ Monday, these had the largest net inflows of money $FXI… https://t.co/lKu9dkV98t
- RT @seeitmarket: NEW Article: "National Oilwell Varco (NOV) Cycle Outlook: Stock Topping?" - https://t.co/bxXkHkGBQe by @askSlim $NOV $S…
- RT @seeitmarket: NEW Article: "National Oilwell Varco (NOV) Cycle Outlook: Stock Topping?" - https://t.co/bxXkHkGBQe by @askSlim $NOV $S…
- RT @seeitmarket: NEW Article: "National Oilwell Varco (NOV) Cycle Outlook: Stock Topping?" - https://t.co/bxXkHkGBQe by @askSlim $NOV $S…
- Mammoth Energy Services $TUSK versus Halliburton $HAL Head-To-Head Review https://t.co/cTXbzkc905
- RT @Sarge986: Market Recon: Worried About the Trump Scandal? Buy Planet Fitness $XOM $HAL $SLB $PLNT IBM $CSX $LRCX $UAL https://t.co/b4FR…
- Market Recon: Worried About the Trump Scandal? Buy Planet Fitness $XOM $HAL $SLB $PLNT IBM $CSX $LRCX $UAL https://t.co/b4FREpW5Li
$WING
- Scan results - Expansion Breakout today: $ERI $CCJ $CVNA $WING $ECL $WRD $ORAN $VLO $KRNT $BT ... https://t.co/nfKdsGhwnd
- Scan results - MACD Bullish Signal Line Cross today: $CSU $ILG $WING $LSTR $JBHT $NXST $CRCM $MRTN $ROL $ANTX ... https://t.co/JKIwpnpGfe
- Scan results - New 52 Week Closing High today: $ERI $NXEO $VNOM $CVNA $WING $RGNX $ECL $LMNX $LOXO $WRD ... https://t.co/qxDLqvPlq5
- Top 5 EPS #WallStreet #Money #Stocks $NAV $JBHT $WING $ALKS $CVS Get Top 20 stocks, Quote & Chart of the Day Free… https://t.co/L7xb3rIsV0
- Big Call Activity https://t.co/B6IlNKq3kX $BHGE $WING $JD $SLB $WDC $TPX $IMAX $AMD $MDXG $GM $ALRM $LVS $IPG $AKRX $AMWD $OLED $TWTR $AAPL
- All time highs hit $BURL $ERI $HLF $LMAT $LULU $RUTH $VLO $WING $WWE $IQ $FTNT $DENN
$MAC
- #MAC/#BTC: Ask: 0.00000429 BTC Bid: 0.00000402 BTC https://t.co/UQx7PuoCVP #Machinecoin #Bitcoin $MAC $BTC [16.04.2018 21:00:19 UTC]
- https://t.co/XK3KcE4X4f $PND $SPRTS $IND $MAC $FXE $EXN $TRI $EUR $TOKEN $POT $ETB $BLITZ $TSTR $PRN $LUN $PGL… https://t.co/QcOKxI44Uo
- Brokers Issue Forecasts for Macerich’s FY2019 Earnings $MAC https://t.co/TTSXug54yb
- #MAC/#BTC: Ask: 0.00000508 BTC Bid: 0.00000456 BTC https://t.co/UQx7PuoCVP #Machinecoin #Bitcoin $MAC $BTC [17.04.2018 09:00:21 UTC]
- ⌛️ BINANCE REGISTRATIONS OPEN! ⌛️ Register RIGHT NOW at the #1 Crypto Exchange: ➡️ https://t.co/KXOSJeYkWE ⬅️ (P… https://t.co/M9bzfz1V9N
- Analysts Anticipate Macerich $MAC to Post $0.81 Earnings Per Share https://t.co/Tj0FKfAtZQ
- Macerich $MAC Expected to Announce Earnings of $0.81 Per Share https://t.co/XUYPVzFJGN
$NAV
- RT @Super1NYC: Top % Gainers: $CGIX 37%, $HMNY 31%, $I $ERI $CVNA $HEAR $EBIO $SRNE $TRNC $UEC $WATT $NAV $CRON $PCRX $ILG $MDXG $JBHT $TND…
- RT @theflynews: On The Fly: Top stock stories for Monday $AMZN $CVS $WBA $ABC $MCK $CAH $TSLA $NFLX $BAC $WPP $ERI $TPCA $NAV $VLKAY $ACIA…
- RT @theflynews: On The Fly: Top stock stories for Monday $AMZN $CVS $WBA $ABC $MCK $CAH $TSLA $NFLX $BAC $WPP $ERI $TPCA $NAV $VLKAY $ACIA…
- RT @SwingTradeBot: Scan results - MACD Bullish Centerline Cross today: $NAV $GWPH $MRTN $KRNT $CE $EPD $COST $LUK $ALSN $UNH ... https://t.…
- Scan results - MACD Bullish Centerline Cross today: $NAV $GWPH $MRTN $KRNT $CE $EPD $COST $LUK $ALSN $UNH ... https://t.co/YN1VrBWUAJ
- Scan results - Crossed Above 50 DMA today: $NAV $ILG $JBHT $GNRC $MCK $VMW $ATUS $AOS $DCP $HUBG ... https://t.co/QklaH8Cvyb
- RT @ProfitTradeRoom: 1️⃣2️⃣Biggest Market Gainers $CGIX $HMNY $I $ERI $PSDV $HEAR $EBIO $EYEG $SRNE $UEC $NAV $WATT $ARGS $CRON $JONE $NM $…
- 1️⃣2️⃣Biggest Market Gainers $CGIX $HMNY $I $ERI $PSDV $HEAR $EBIO $EYEG $SRNE $UEC $NAV $WATT $ARGS $CRON $JONE… https://t.co/sbJuZm2ReF
- Top 5 EPS #WallStreet #Money #Stocks $NAV $JBHT $WING $ALKS $CVS Get Top 20 stocks, Quote & Chart of the Day Free… https://t.co/L7xb3rIsV0
- Join our pump group for fast bitcoin https://t.co/sFUodj0HoC $NAV $EOS $ZEC $ELF $XZC $MCO $ETH $HSR $BTG $CTR… https://t.co/TruyjLAmxV
- Join our biggest pump Binance group https://t.co/qGQzcfEJ7Y $BNT $TRX $IOTA $CDT $MCO $BCC $BCPT $NAV $XLM $LUN… https://t.co/rrRs7dcQJy
- Join our biggest pump Binance group https://t.co/hZ4Z0HtoeE $NEO $ZRX $ICN $BCC $LTC $DASH $VIBE $ARN $OST $NAV… https://t.co/eSzfRiqUdm
- Gainers $CGIX $HMNY $ERI $PSDV $HEAR $EBIO $EYEG $SRNE $UEC $NAV $WATT $ARGS $CRON $JONE $NM $PCRX $ILG $MDXG $TSRO… https://t.co/kwBZHEC2xS
- RT @Super1NYC: Top % Gainers: $CGIX 40%, $RGSE 26%, $ERI $I $FSCT $FTD $ENT $HEAR $NAV $APTO $RGNX $TRNC $MVIS $RUBI $CVNA $LGCY $APRN $LOX…
- RT @pennystockprodi: $ERI $CVNA $HEAR $EBIO $SRNE $TRNC $UEC $WATT $NAV $CRON $PCRX $ILG $MDXG $JBHT $TNDM $TSRO $WRD $GPRO Exactly why Ma…
- $ERI $CVNA $HEAR $EBIO $SRNE $TRNC $UEC $WATT $NAV $CRON $PCRX $ILG $MDXG $JBHT $TNDM $TSRO $WRD $GPRO Exactly why… https://t.co/xHYRAwJ6zN
- We made 25% with our last pump signal https://t.co/EfgxBYA97d $LSK $BRD $IOTA $MCO $OMG $EOS $BQX $NAV $POE $BTC… https://t.co/hP7ui2ypqp
- We will pump on binance at 10PM https://t.co/B1gw2ZUEuW $WINGS $DNT $POE $GAS $HSR $ETH $QSP $MOD $NAV $NEBL $KMD… https://t.co/dKslX9Y9Ex
- We will pump on binance at 10PM https://t.co/oS9bj7nVQY $STORJ $BRD $REQ $XRP $XMR $ELF $XLM $NAV $OCN $AMB $BNT… https://t.co/1Uxx7AaEly
- We will pump coin on Binance today https://t.co/UnQhmXKyve $BQX $NEBL $DASH $BTG $CND $NAV $XRP $MTL $OCN $DGD… https://t.co/t9h5t4HpPq
- Top Gainers $CGIX $HMNY $ERI $PSDV $HEAR $EBIO $EYEG $SRNE $UEC $NAV $WATT $ARGS $CRON $JONE $NM $PCRX $ILG $MDXG $TSRO $TNDM $JBHT $RGSE
- RT @CoinSignalBot: 30 min #RSI Signals: $BTC - $GBG: 33.98 $BTC - $DCR: 36.88 $BTC - $SRN: 38.89 $BTC - $ZEC: 39.24 $BTC - $NAV: 41.57 $BT…
- 30 min #RSI Signals: $BTC - $GBG: 33.98 $BTC - $DCR: 36.88 $BTC - $SRN: 38.89 $BTC - $ZEC: 39.24 $BTC - $NAV: 41.5… https://t.co/yrIi5YGpP0
- Join our pump group for fast bitcoin https://t.co/hZ31I7rcP0 $FUEL $TRX $LEND $NAV $ETH $OMG $BRD $NANO $LUN $ARK… https://t.co/mzR5olufsS
- Join our pump group for fast bitcoin https://t.co/TV8epcEHKY $ENJ $MDA $KNC $WINGS $BRD $MCO $ONT $GXS $NAV $EDO… https://t.co/vprhQNRvL9
$DVA
- $IHF Good day for health care providers. Broke downtrend and above key moving averages for first time in a month. A… https://t.co/XHUssi9J9C
- Contrasting Davita $DVA & Caladrius Biosciences $CLBS https://t.co/8O2iSYxE7W
- Head-To-Head Survey: Davita $DVA versus Caladrius Biosciences $CLBS https://t.co/MnYQM0nZpT
- Head-To-Head Survey: Davita $DVA versus Caladrius Biosciences $CLBS https://t.co/FxsSWccm4I #stocks
- $DVA Max Pain is 67.50 for maturity 04/20/2018. #maxpain #options https://t.co/j8AruYRhAf https://t.co/dXVsoEzg7N
- Reviewing Davita $DVA & Catasys $CATS https://t.co/0aV2D8EdRj #stocks
- Catasys $CATS versus Davita $DVA Head to Head Comparison https://t.co/HzrpXM8nVY
- Reviewing Davita $DVA & Catasys $CATS https://t.co/4WdiR1X4iR
- Reviewing Davita $DVA & Catasys $CATS https://t.co/sK96VKVBwJ
- $DVA DaVita Inc. Schedules 1st Quarter 2018 Investor Conference Call From our Stock News Alerts App
$MRTN
- RT @SwingTradeBot: Scan results - MACD Bullish Centerline Cross today: $NAV $GWPH $MRTN $KRNT $CE $EPD $COST $LUK $ALSN $UNH ... https://t.…
- Scan results - MACD Bullish Centerline Cross today: $NAV $GWPH $MRTN $KRNT $CE $EPD $COST $LUK $ALSN $UNH ... https://t.co/YN1VrBWUAJ
- Scan results - MACD Bullish Signal Line Cross today: $CSU $ILG $WING $LSTR $JBHT $NXST $CRCM $MRTN $ROL $ANTX ... https://t.co/JKIwpnpGfe
1)
quote {symbol XRAY companyName {DENTSPLY SIRONA Inc.} primaryExchange {Nasdaq Global Select} sector Healthcare calculationPrice sip open 49.37 openTime 1523885400506 close 50.19 closeTime 1523908800163 high null low null latestPrice 50.74 latestSource {15 minute delayed price} latestTime {8:53:52 AM} latestUpdate 1523969632683 latestVolume 252 iexRealtimePrice 0 iexRealtimeSize 0 iexLastUpdated 0 delayedPrice 50.74 delayedPriceTime 1523969632683 previousClose 50.19 change 0.55 changePercent 0.01096 iexMarketPercent 0 iexVolume 0 avgTotalVolume 2258900 iexBidPrice 0 iexBidSize 0 iexAskPrice 0 iexAskSize 0 marketCap 11536660794 peRatio 19.08 week52High 68.98 week52Low 48.25 ytdChange -0.2511481201863252}
2)
quote {symbol SLB companyName {Schlumberger N.V.} primaryExchange {New York Stock Exchange} sector Energy calculationPrice sip open 68.32 openTime 1523885400711 close 68.52 closeTime 1523908810173 high null low null latestPrice 68.52 latestSource {15 minute delayed price} latestTime {8:53:39 AM} latestUpdate 1523969619490 latestVolume 70267 iexRealtimePrice 0 iexRealtimeSize 0 iexLastUpdated 0 delayedPrice 68.52 delayedPriceTime 1523969619490 previousClose 68.52 change 0 changePercent 0 iexMarketPercent 0 iexVolume 0 avgTotalVolume 7013000 iexBidPrice 0 iexBidSize 0 iexAskPrice 0 iexAskSize 0 marketCap 94965783096 peRatio 45.68 week52High 80.35 week52Low 61.02 ytdChange -0.007428352898911802}
3)
quote {symbol EBAY companyName {eBay Inc.} primaryExchange {Nasdaq Global Select} sector {Consumer Cyclical} calculationPrice sip open 40.22 openTime 1523885400164 close 40.19 closeTime 1523908800470 high null low null latestPrice 40.6 latestSource {15 minute delayed price} latestTime {8:51:39 AM} latestUpdate 1523969499330 latestVolume 4191 iexRealtimePrice 0 iexRealtimeSize 0 iexLastUpdated 0 delayedPrice 40.6 delayedPriceTime 1523969499330 previousClose 40.19 change 0.41 changePercent 0.0102 iexMarketPercent 0 iexVolume 0 avgTotalVolume 9464723 iexBidPrice 0 iexBidSize 0 iexAskPrice 0 iexAskSize 0 marketCap 40348217111 peRatio 24.61 week52High 46.99 week52Low 31.89 ytdChange 0.055964266946925786}
4)
quote {symbol NTAP companyName {NetApp Inc.} primaryExchange {Nasdaq Global Select} sector Technology calculationPrice sip open 68.15 openTime 1523885400690 close 68.27 closeTime 1523908800286 high null low null latestPrice 69.1 latestSource {15 minute delayed price} latestTime {9:00:27 AM} latestUpdate 1523970027328 latestVolume 99 iexRealtimePrice 0 iexRealtimeSize 0 iexLastUpdated 0 delayedPrice 69.1 delayedPriceTime 1523970027328 previousClose 68.27 change 0.83 changePercent 0.01216 iexMarketPercent 0 iexVolume 0 avgTotalVolume 2963712 iexBidPrice 0 iexBidSize 0 iexAskPrice 0 iexAskSize 0 marketCap 18513459123 peRatio 29.03 week52High 69.1 week52Low 37.43 ytdChange 0.23684258202438524}
5)
quote {symbol PEG companyName {Public Service Enterprise Group Incorporated} primaryExchange {New York Stock Exchange} sector Utilities calculationPrice previousclose open 50.44 openTime 1523885400554 close 50.41 closeTime 1523908911112 high 50.61 low 50.01 latestPrice 50.41 latestSource {Previous close} latestTime {April 16, 2018} latestUpdate 1523836800000 latestVolume 3034298 iexRealtimePrice 0 iexRealtimeSize 0 iexLastUpdated 0 delayedPrice 50.327 delayedPriceTime 1523911962858 previousClose 50.41 change 0 changePercent 0 iexMarketPercent 0 iexVolume 0 avgTotalVolume 3147777 iexBidPrice 0 iexBidSize 0 iexAskPrice 0 iexAskSize 0 marketCap 25445188880 peRatio 17.2 week52High 53.28 week52Low 41.67 ytdChange -0.002052908418904247}
6)
quote {symbol NUE companyName {Nucor Corporation} primaryExchange {New York Stock Exchange} sector {Basic Materials} calculationPrice previousclose open 62.03 openTime 1523885400656 close 62.46 closeTime 1523908869747 high 62.64 low 61.62 latestPrice 62.46 latestSource {Previous close} latestTime {April 16, 2018} latestUpdate 1523836800000 latestVolume 1776623 iexRealtimePrice 0 iexRealtimeSize 0 iexLastUpdated 0 delayedPrice 62.46 delayedPriceTime 1523911326000 previousClose 62.46 change 0 changePercent 0 iexMarketPercent 0 iexVolume 0 avgTotalVolume 2448056 iexBidPrice 0 iexBidSize 0 iexAskPrice 0 iexAskSize 0 marketCap 19867986408 peRatio 17.59 week52High 70.48 week52Low 51.67 ytdChange -0.05507236729636633}
7)
quote {symbol MRK companyName {Merck & Company Inc. (new)} primaryExchange {New York Stock Exchange} sector Healthcare calculationPrice sip open 57.78 openTime 1523885411615 close 58.65 closeTime 1523908839753 high null low null latestPrice 59.75 latestSource {15 minute delayed price} latestTime {9:02:35 AM} latestUpdate 1523970155862 latestVolume 81276 iexRealtimePrice 0 iexRealtimeSize 0 iexLastUpdated 0 delayedPrice 59.75 delayedPriceTime 1523970155862 previousClose 58.65 change 1.1 changePercent 0.01876 iexMarketPercent 0 iexVolume 0 avgTotalVolume 12141673 iexBidPrice 0 iexBidSize 0 iexAskPrice 0 iexAskSize 0 marketCap 160889705058 peRatio 15.01 week52High 66.41 week52Low 52.83 ytdChange 0.05234638254809574}
8)
quote {symbol PPL companyName {PPL Corporation} primaryExchange {New York Stock Exchange} sector Utilities calculationPrice sip open 27.91 openTime 1523885409900 close 28.06 closeTime 1523908946611 high null low null latestPrice 28.04 latestSource {15 minute delayed price} latestTime {8:54:10 AM} latestUpdate 1523969650286 latestVolume 500 iexRealtimePrice 0 iexRealtimeSize 0 iexLastUpdated 0 delayedPrice 28.04 delayedPriceTime 1523969650286 previousClose 28.06 change -0.02 changePercent -0.00071 iexMarketPercent 0 iexVolume 0 avgTotalVolume 7217275 iexBidPrice 0 iexBidSize 0 iexAskPrice 0 iexAskSize 0 marketCap 19467510396 peRatio 12.46 week52High 40.2 week52Low 27.08 ytdChange -0.06919040131626968}
9)
quote {symbol DISCA companyName {Discovery Inc. Series A Common Stock} primaryExchange {Nasdaq Global Select} sector {Consumer Cyclical} calculationPrice previousclose open 22.9 openTime 1523885400743 close 23.4 closeTime 1523908800447 high 23.465 low 22.46 latestPrice 23.4 latestSource {Previous close} latestTime {April 16, 2018} latestUpdate 1523836800000 latestVolume 4079380 iexRealtimePrice 0 iexRealtimeSize 0 iexLastUpdated 0 delayedPrice 23.4 delayedPriceTime 1523911300000 previousClose 23.4 change 0 changePercent 0 iexMarketPercent 0 iexVolume 0 avgTotalVolume 5538056 iexBidPrice 0 iexBidSize 0 iexAskPrice 0 iexAskSize 0 marketCap 11762420296 peRatio 11.76 week52High 30.25 week52Low 15.99 ytdChange 0.01254868022501078}
10)
quote {symbol DWDP companyName {DowDuPont Inc.} primaryExchange {New York Stock Exchange} sector {Basic Materials} calculationPrice sip open 66.69 openTime 1523885418601 close 67.01 closeTime 1523908815366 high null low null latestPrice 67.5 latestSource {15 minute delayed price} latestTime {9:03:41 AM} latestUpdate 1523970221833 latestVolume 3015 iexRealtimePrice 0 iexRealtimeSize 0 iexLastUpdated 0 delayedPrice 67.5 delayedPriceTime 1523970221833 previousClose 67.01 change 0.49 changePercent 0.00731 iexMarketPercent 0 iexVolume 0 avgTotalVolume 9705606 iexBidPrice 0 iexBidSize 0 iexAskPrice 0 iexAskSize 0 marketCap 157001302283 peRatio 48.91 week52High 77.08 week52Low 61.27 ytdChange -0.0632046760080579}
11)
quote {symbol HAL companyName {Halliburton Company} primaryExchange {New York Stock Exchange} sector Energy calculationPrice previousclose open 50.82 openTime 1523885400357 close 50.76 closeTime 1523908835509 high 51 low 50.07 latestPrice 50.76 latestSource {Previous close} latestTime {April 16, 2018} latestUpdate 1523836800000 latestVolume 6540593 iexRealtimePrice 0 iexRealtimeSize 0 iexLastUpdated 0 delayedPrice 50.81 delayedPriceTime 1523911608009 previousClose 50.76 change 0 changePercent 0 iexMarketPercent 0 iexVolume 0 avgTotalVolume 8643869 iexBidPrice 0 iexBidSize 0 iexAskPrice 0 iexAskSize 0 marketCap 44422616589 peRatio 41.61 week52High 57.86 week52Low 38.181 ytdChange 0.02717688244935946}
12)
quote {symbol WING companyName {Wingstop Inc.} primaryExchange {Nasdaq Global Select} sector {Consumer Cyclical} calculationPrice sip open 48.81 openTime 1523885400579 close 51.09 closeTime 1523908800456 high null low null latestPrice 52.08 latestSource {15 minute delayed price} latestTime {8:49:56 AM} latestUpdate 1523969396361 latestVolume 50 iexRealtimePrice 0 iexRealtimeSize 0 iexLastUpdated 0 delayedPrice 52.08 delayedPriceTime 1523969396361 previousClose 51.09 change 0.99 changePercent 0.01938 iexMarketPercent 0 iexVolume 0 avgTotalVolume 449571 iexBidPrice 0 iexBidSize 0 iexAskPrice 0 iexAskSize 0 marketCap 1518459687 peRatio 70.38 week52High 52.08 week52Low 27.785 ytdChange 0.3033362755552383}
13)
quote {symbol MAC companyName {Macerich Company (The)} primaryExchange {New York Stock Exchange} sector {Real Estate} calculationPrice sip open 57.94 openTime 1523885400503 close 57.85 closeTime 1523908922366 high null low null latestPrice 57.85 latestSource {15 minute delayed price} latestTime {8:36:04 AM} latestUpdate 1523968564289 latestVolume 38 iexRealtimePrice 0 iexRealtimeSize 0 iexLastUpdated 0 delayedPrice 57.85 delayedPriceTime 1523968564289 previousClose 57.85 change 0 changePercent 0 iexMarketPercent 0 iexVolume 0 avgTotalVolume 1288550 iexBidPrice 0 iexBidSize 0 iexAskPrice 0 iexAskSize 0 marketCap 8148295026 peRatio 14.68 week52High 69.73 week52Low 52.12 ytdChange -0.12078592771142925}
14)
quote {symbol NAV companyName {Navistar International Corporation} primaryExchange {New York Stock Exchange} sector Industrials calculationPrice sip open 39.2 openTime 1523885566073 close 40.71 closeTime 1523908925309 high null low null latestPrice 41.58 latestSource {15 minute delayed price} latestTime {9:02:43 AM} latestUpdate 1523970163295 latestVolume 1005 iexRealtimePrice 0 iexRealtimeSize 0 iexLastUpdated 0 delayedPrice 41.58 delayedPriceTime 1523970163295 previousClose 40.71 change 0.87 changePercent 0.02137 iexMarketPercent 0 iexVolume 0 avgTotalVolume 1151859 iexBidPrice 0 iexBidSize 0 iexAskPrice 0 iexAskSize 0 marketCap 4103501718 peRatio 50.1 week52High 47.73 week52Low 23.02 ytdChange -0.06692642677057074}
15)
quote {symbol DVA companyName {DaVita Inc.} primaryExchange {New York Stock Exchange} sector Healthcare calculationPrice previousclose open 63.28 openTime 1523885447116 close 63.17 closeTime 1523908913323 high 63.42 low 62.32 latestPrice 63.17 latestSource {Previous close} latestTime {April 16, 2018} latestUpdate 1523836800000 latestVolume 1286347 iexRealtimePrice 0 iexRealtimeSize 0 iexLastUpdated 0 delayedPrice 63.17 delayedPriceTime 1523911309000 previousClose 63.17 change 0 changePercent 0 iexMarketPercent 0 iexVolume 0 avgTotalVolume 1741498 iexBidPrice 0 iexBidSize 0 iexAskPrice 0 iexAskSize 0 marketCap 11496940000 peRatio 18.36 week52High 80.71 week52Low 52.51 ytdChange -0.12917011304108084}
16)
quote {symbol MRTN companyName {Marten Transport Ltd.} primaryExchange {Nasdaq Global Select} sector Industrials calculationPrice previousclose open 22.95 openTime 1523885400686 close 23.5 closeTime 1523908800261 high 23.65 low 22.95 latestPrice 23.5 latestSource {Previous close} latestTime {April 16, 2018} latestUpdate 1523836800000 latestVolume 460888 iexRealtimePrice 0 iexRealtimeSize 0 iexLastUpdated 0 delayedPrice 23.5 delayedPriceTime 1523912310047 previousClose 23.5 change 0 changePercent 0 iexMarketPercent 0 iexVolume 0 avgTotalVolume 317016 iexBidPrice 0 iexBidSize 0 iexAskPrice 0 iexAskSize 0 marketCap 1282334934 peRatio 37.9 week52High 29.6 week52Low 12.99 ytdChange 0.13372668020706183}